SM-030
Melasma and other hyperpigmentation disorders of the skin
UnknownActive
Key Facts
Indication
Melasma and other hyperpigmentation disorders of the skin
Phase
Unknown
Status
Active
Company
About DermBiont
DermBiont is a private, pre-revenue biotech focused on revolutionizing dermatology treatment through its lead asset, SM-030, for melasma. The company employs a highly experienced leadership team with a proven track record in dermatology drug development and exits. Its strategy centers on a capital-efficient clinical development pathway to address a significant unmet need in the hyperpigmentation market, aiming for FDA approval and market leadership.
View full company profile